Analysis of the MILES cohort reveals determinants of disease progression and?treatment response in lymphangioleiomyomatosis.
Gupta N, Lee HS, Young LR, Strange C, Moss J, Singer LG, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP, Goldberg HJ, Downey GP, Taveira-DaSilva AM, Krischer JP, Setchell K, Trapnell BC, Inoue Y, McCormack FX. Analysis of the MILES cohort reveals determinants of disease progression and?treatment response in lymphangioleiomyomatosis. Eur Respir J. 2019 04; 53(4).